Edition:
United States

Marinus Pharmaceuticals Inc (MRNS.OQ)

MRNS.OQ on NASDAQ Stock Exchange Global Market

6.22USD
16 Feb 2018
Change (% chg)

$-0.19 (-2.96%)
Prev Close
$6.41
Open
$6.45
Day's High
$6.63
Day's Low
$6.20
Volume
150,308
Avg. Vol
335,787
52-wk High
$9.86
52-wk Low
$1.13

Chart for

About

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral... (more)

Overall

Beta: 2.26
Market Cap(Mil.): $251.48
Shares Outstanding(Mil.): 40.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.03 17.27
EPS (TTM): -- -- --
ROI: -- 14.00 35.43
ROE: -- 15.34 17.10

BRIEF-Marinus Pharmaceuticals files for mixed shelf of up to $200 mln

* Marinus Pharmaceuticals Inc - files for a mixed shelf of up to $200 million - SEC filing‍​ Source text: [http://bit.ly/2z23P1a] Further company coverage:

Oct 31 2017

BRIEF-Marinus Pharmaceuticals qtrly loss per share $0.15‍​

* Marinus Pharmaceuticals provides business update and reports third quarter 2017 financial results

Oct 31 2017

BRIEF-Bain Capital Life Sciences Fund reports 14.4 pct passive stake in Marinus Pharmaceuticals

* Bain Capital Life Sciences Fund L.P reports 14.4 percent passive stake in Marinus Pharmaceuticals Inc as of Sept 19, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2fUP6u2) Further company coverage:

Sep 28 2017

BRIEF-Marinus Pharmaceuticals announces pricing of public offering of common stock

* Marinus Pharmaceuticals announces pricing of public offering of common stock

Sep 15 2017

BRIEF-Marinus Pharmaceuticals announces public offering of common stock

* Marinus Pharmaceuticals Inc announces public offering of common stock

Sep 14 2017

BRIEF-Marinus announces successful clinical trial results

* Marinus announces successful clinical trial results and declares CDKL5 disorder its lead pediatric orphan epilepsy program for ganaxolone

Sep 11 2017

Earnings vs. Estimates